Arpita Dutt | TalkMarkets | Page 4

Arpita Dutt

Analyst at Zacks Research Pvt. Ltd.
Contributor's Links: Zacks Investment Research
Arpita has been an equity analyst at Zacks Investment Research since March, 2004.
Following: 12 Followers: 1927

All Contributions

Latest Posts
49 to 64 of 92 Posts
<<< 1 2 3 4 5 6 >>>
Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs Under EU Review
Wednesday, January 25, 2017 2:07 PM EDT
There were quite a few updates on the regulatory front this week with Synergy gaining FDA approval for its constipation drug, while both Gilead and AbbVie got accelerated assessment for their HCV drugs in the EU.
In this article: SGYP, GILD, ABBV, ALIOF, JNJ, VRTX, REGN, CELG
Read
Two Key FDA Decisions To Watch Out For In January 2017
Monday, January 2, 2017 3:29 PM EDT
Several drug companies could see regulatory milestones passed in January 2017. Here's a look at a couple of important regulatory events scheduled for this month.
In this article: INCY, LLY, SGYP
Read
Cempra Plunges To 52-Week Low, Shire Drug Label Expanded
Friday, December 30, 2016 10:33 AM EDT
It was a relatively slow week for pharma stocks though a couple of companies suffered regulatory setbacks with the FDA issuing complete response letters (CRLs) for their regulatory applications.
In this article: AMPH, AZN, BMY, CEMP, MRK, MYL, SHPG
Read
J&J Back In Talks With Actelion, Teva Settles Corruption Probe
Friday, December 23, 2016 1:37 PM EDT
Several tuck-in deals and licensing agreements were announced this week while healthcare giant Johnson & Johnson is back in exclusive talks with Actelion regarding a possible deal.
In this article: AGN, JNJ, MRK, NVS, TEVA Also: BMY, PFE, LLY
Read
4 Biotech Stocks That More Than Doubled In 2016
Thursday, December 22, 2016 11:47 AM EDT
2016 has not been a great year for biotech stocks, which were under intense pressure with issues like increasing political and media focus on high price tags for drugs, and the changing competitive scenario weighing on the sector.
In this article: CLCD, EXEL, TSRO, AKAO
Read
Conatus Soars On Novartis Deal, Early FDA Nod For Clovis Drug
Wednesday, December 21, 2016 10:55 AM EDT
Conatus is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant, Novartis. Investors applauded the deal sending the company’s shares soaring 141.3%.
In this article: ALIOF, ALXN, BIIB, CLVS, GILD, CNAT, TSRO
Read
Actelion Remains In M&A Spotlight, ASH Data In Focus
Wednesday, December 7, 2016 6:01 PM EDT
Switzerland-based Actelion continued to be a part of acquisition chatter with Sanofi now rumored to be interested in the company.
In this article: ALIOF, AMGN, CELG, VRTX, ABBV, AGIO, KITE
Read
Play The Trump Factor With These 4 Large-Cap Stocks
Tuesday, December 6, 2016 2:38 PM EDT
2016 was a year full of surprises and uncertainty with the markets facing volatility in the face of economic and political pressure. However, the volatility that was experienced in the run-up to the elections has subsided somewhat.
In this article: BAH, MCD, RF, REGN
Read
Lilly Alzheimer's Drug Fails, J&J In Acquisition Talks With ALIOF
Monday, November 28, 2016 11:59 AM EDT
Does Johnson & Johnson’s interest in acquiring Actelion imply the beginning of increased merger and acquisition (M&A) activity in the pharma and biotech sector?
In this article: AGN, AZN, BMY, JNJ, LLY, MRK, ALIOF
Read
3 Top-Ranked Retail Stocks Worth A Look Ahead Of Black Friday
Tuesday, November 22, 2016 1:18 PM EDT
With Thanksgiving around the corner, a busy period is coming up for retail stocks. Black Friday is a very important day for e-commerce stocks and retailers with many companies reporting their highest profits on this day.
In this article: TGT, BBY, JWN Also: AMZN, WMT, KSS
Read
4 Restaurant Stocks To Avoid As Environment Remains Tough
Monday, November 21, 2016 11:10 AM EDT
The U.S. restaurant industry is facing a tough operating environment with factors like rising labor costs, increasing employee turnover, declining traffic and higher non-discretionary spending weighing on the sector.
In this article: NDLS, FRSH, LOCO, BJRI
Read
Data Presented At ACR, Bristol-Myers Inks Immuno-Oncology Deal
Friday, November 18, 2016 8:30 AM EDT
Several companies were present at the annual meeting of the American College of Rheumatology (ACR) presenting data on approved as well as pipeline candidates. Bristol-Myers announced an immune-oncology deal.
In this article: AGN, BMY, JNJ, PFE, SNY, RHHBY, TEVA
Read
Biotech Stocks Soar On Election Results, Gilead HBV Drug Approved
Wednesday, November 16, 2016 3:30 PM EDT
The biotech sector responded favorably to Trump’s victory on hopes that there will be fewer drug pricing headwinds considering Trump was not as vocal as Hillary Clinton about rising drug prices and excessive price hikes.
In this article: ALNY, REGN, AMGN, GILD, MDCO, VRTX, ABBV
Read
6 Things You Need To Know About Teva's Q3 Earnings
Wednesday, November 16, 2016 1:15 PM EDT
Teva Pharmaceutical Industries Limited reported third quarter results yesterday. With the company missing revenue estimates and lowering its outlook for the year, shares were down 8.4%.
In this article: TEVA Also: MYL, BAYRY, MNK
Read
5 Pharma Stocks In Focus On World Diabetes Day
Monday, November 14, 2016 1:21 PM EDT
Today on World Diabetes Day, here is a look at some of the key pharma companies in the diabetes market.
In this article: NVO, SNY, LLY, MRK, PFE
Read
Fundamentals Remain Strong In The Pharma Sector
Saturday, November 5, 2016 6:49 PM EDT
Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs, a changing competitive scenario and mixed results, the sector’s fundamentals remain strong.
In this article: AGN, BMY, MRK, ARIA, AMGN, BIIB, CELG
Read
49 to 64 of 92 Posts
<<< 1 2 3 4 5 6 >>>